Dianthus Therapeutics, Inc. Common Stock (DNTH)
Health Care – PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 92
- Market Cap
- $6.1B
About Dianthus Therapeutics, Inc. Common Stock
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
SentiSense also tracks daily options readings for Dianthus Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Dianthus Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.